Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ENVISION: Givosiran in Acute Hepatic Porphyria
NCT03338816Phase 3Completed
- Sponsor
- Alnylam Pharmaceuticals
- Start
- Nov 2017
- Primary completion
- Jan 2019
- Modality
- Conjugated siRNA, Chemically Modified siRNA
- Countries
- 18
01
Overview
A Phase 3 trial of givosiran in acute hepatic porphyria (AHP), sponsored by Alnylam Pharmaceuticals. Started Nov 2017; status: completed.
02
Drugs
givosiran
03
Conditions
acute hepatic porphyria (AHP)
Beyond the preview
Go deeper on NCT03338816.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03338816.